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Abstract
Background: Pressure ulcers (PUs) are a major clinical problem that constitutes a tremendous economic burden on
healthcare systems. Deep tissue injury (DTI) is a unique serious type of pressure ulcer that arises in skeletal muscle
tissue. DTI arises in part because skeletal muscle tissues are more susceptible than skin to external compression.
Unfortunately, few effective therapies are currently available for muscle injury. Basic fibroblast growth factor (bFGF),
a potent mitogen and survival factor for various cells, plays a crucial role in the regulation of muscle development
and homeostasis. The main purpose of this study was to test whether local administration of bFGF could accelerate
muscle regeneration in a rat DTI model.
Methods: Male Sprague Dawley (SD) rats (age 12 weeks) were individually housed in plastic cages and a DTI PU model
was induced according to methods described before. Animals were randomly divided into three groups: a normal group,
a PU group treated with saline, and a PU group treated with bFGF (10 μg/0.1 ml) subcutaneously near the wound.
Results: We found that application of bFGF accelerated the rate of wound closure and promoted cell proliferation and
tissue angiogenesis. In addition, compared to saline administration, bFGF treatment prevented collagen deposition, a
measure of fibrosis, and up-regulated the myogenic marker proteins MyHC and myogenin, suggesting bFGF
promoted injured muscle regeneration. Moreover, bFGF treatment increased levels of myogenesis-related
proteins p-Akt and p-mTOR.
Conclusions: Our findings show that bFGF accelerated injured skeletal muscle regeneration through activation
of the PI3K/Akt/mTOR signaling pathway and suggest that administration of bFGF is a potential therapeutic
strategy for the treatment of skeletal muscle injury in PUs.
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Background
Pressure ulcers (PUs) are defined as localized break-
down ulcerated tissue caused by sustained mechanical
pressure in the body support interface. The preva-
lence of PUs in the USA is 3 million, and PUs are a
particularly common problem among older adults in
all health care settings [1]. PUs are a major source of
morbidity, mortality, and health care costs. The
annual cost of PUs in the USA is estimated to be be-
tween USD 9.1 billion and USD 11.6 billion [2] and
is expected to increase with the drastic growth of the
elderly population, the cohort who are most suscep-
tible to PUs.
The term of “Deep Tissue Injury (DTI)” was put for-
ward by the National Pressure Ulcer Advisory Panel
(NPUAP) to define a unique type of PUs that develop as
a consequence of damage to underlying soft tissues, such
as muscles and bones. DTI develop into cavity-shaped
large open wounds that when undiagnosed or not
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treated in a timely manner can lead to complications
such as sepsis, myocardial infarction, renal failure, and
multiple organ dysfunction [3]. Pressure, shear, and is-
chemia have been identified as causes of PUs, and at the
cellular and molecular levels, oxidative stress, autophagy,
and apoptosis play important roles in the development
and progression of pressure-induced DTI [4, 5].
Skeletal muscle injury and repair are complex pro-
cesses, involving degeneration, inflammation, regener-
ation, and fibrosis. Skeletal muscle tissue regeneration
occurs through the activation of satellite cells, a popula-
tion of quiescent myogenic cells, located between the
basal lamina and plasma membrane of the muscle fiber
[6, 7]. Upon skeletal muscle injury, satellite cells prolifer-
ate and differentiate into mature myotubes that facilitate
skeletal muscle regeneration [8]. However, it is generally
assumed that the mere presence of satellite cells is insuf-
ficient to ensure rapid functional recovery of injured
muscle. The release of appropriate growth factors, cyto-
kines, and the establishment of a suitable microenviron-
ment are also important in an effective myogenic
response [9, 10].
Among the molecules thought to be involved in the
myogenic response, fibroblast growth factors (FGFs) have
diverse roles in cell proliferation, differentiation, migra-
tion, and survival in most mesoderm and neuroectoderm-
derived cells [11]. The FGF family protein basic fibroblast
growth factor (bFGF) is a potent mitogen and performs
different biological roles in tissue repair and regeneration
[12, 13]. A study has shown that while bFGF messenger
RNA (mRNA) transcripts can be detected in myotubes in
non-injured muscle, in a muscle injury model, bFGF
mRNA can be observed not only in myoblasts but also in
degenerating and regenerated myotubes, suggesting that
bFGF plays a role in the myogenic program [14]. Though
bFGF is widely used to treat diabetic ulcers, gastric ulcers,
surgical wounds, burns, and even spinal cord injury [15],
few studies have focused on the role of bFGF in DTI.
Thus, we aimed to determine whether bFGF could ameli-
orate skeletal muscle injury and improve regeneration of
injured skeletal muscle.
Our previous study showed that bFGF promotes full-
thickness excisional wound healing and reduces scar for-
mation [16]. In the present study, application of bFGF was
extended to ischemia/reperfusion-mediated DTI PU in
rats. The effects of bFGF treatment on DTI were evaluated
by measuring cell proliferation, angiogenesis, myogenesis,
collagen deposition, and activation of signaling pathways.
Methods
Reagents and antibodies
Anti-Akt, anti-p-Akt (Ser473), anti-CD31, anti-actin pri-
mary antibodies, and appropriate secondary antibodies
were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Anti-mTOR and anti-p-mTOR anti-
bodies were purchased from Cell Signaling Technology
(Danvers, MA, USA). Anti-myogenin and anti-MyHC
antibodies were obtained from Abcam (Abcam, Cam-
bridge, MA). All other reagents used were obtained from
Sigma-Aldrich (St. Louis, MO, USA).
Animal treatment
This study was reviewed and approved by the Ethics
Committee for Experimental Animals of Wenzhou
Medical University. Male Sprague Dawley (SD) rats (age
12 weeks) were purchased from the Animal Center of
the Chinese Academy of Sciences and housed under
standard conditions. Animals were individually housed
in plastic cages, and a DTI PU model was induced ac-
cording to methods described in a previous study [17].
Additional file 1 provided detailed information on DTI
model and experiment design. Animals were randomly
divided into three groups: a normal group, a PU group
treated with saline, and a PU group treated with bFGF.
For the PU group treated with bFGF, bFGF solution
(10 μg/0.1 ml) was injected subcutaneously near the
wound on the left side every other day beginning at 0 day
after DTI model, while equivalent volumes of saline were
injected on the right side. The reason for choosing high
dose of bFGF due to our pilot study demonstrated that
1.0 and 5.0 μg dose of bFGF could not promote deep tis-
sue wound healing after 14-day treatment. Photos of the
experimental wounds were taken with a ruler at the dif-
ferent time points, and wound area was assessed using
NIH Image J software.
Hematoxylin–eosin staining and Masson’s trichrome
staining
Histopathological examination by hematoxylin–eosin
(HE) staining and interstitial collagen deposition exam-
ination by Masson’s trichrome staining were performed
on formalin-fixed, paraffin-embedded tissue as previ-
ously described [18]. Images were acquired at ×200 mag-
nification on a Nikon digital camera.
Immunohistochemistry
Immunohistochemical analyses were performed with the
use of primary antibodies against CD31 (1:300) and
PCNA (1:200) on formalin-fixed, paraffin-embedded tis-
sue as previously described [18]. Images were acquired
at ×200 magnification on a Nikon digital camera.
Immunofluorescence
Immunofluorescence analyses were performed with the
use of primary antibodies against CD31 (1:100) or myo-
genin (1:250) on formalin-fixed, paraffin-embedded
tissue as previously described [18]. Cellular nuclei were
counterstained with Hoechst 33258. Labeled sections
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were imaged at ×200 magnification using a Nikon digital
camera.
Western blot analysis
Total protein was extracted from skeletal muscle using
protein extraction reagents. Western blot analyses were
performed with the use of primary antibodies against
myogenin (1:500), MyHC (1:500), Akt, p-Akt (1:500),
mTOR, p-mTOR (1:1000), or actin (1:1000) as previ-
ously described [18]. The protein bands were visualized
and analyzed using the ChemiDicTM XRS+ Imaging
System (Bio-Rad Laboratories, Hercules, CA, USA).
Statistical analysis
Data are presented as mean ± SEM. Statistical significance
was determined by two-way analysis of variance (ANOVA)
test for comparison of three or more experimental condi-
tions. For all statistical comparisons, p values of less than
0.05 were considered statistically significant.
Results
Administration of bFGF decreased wound area
We found that in rats with experimentally induced DTI
PUs, local subcutaneous injection of bFGF significantly de-
creased wound areas starting at the seventh day after DTI
induction. The reduction in wound area was consistently
observed until the end of the observation period, which
was the 21st day after DTI (Additional file 1: Fig. S2A).
Initial wound size was consistent between groups, as
wound area of saline was 72.97 ± 1.181 mm2 and that of
bFGF-treated rats was 73.11 ± 1.275 mm2 (P > 0.05) on
the day of wound induction. For the saline and bFGF
groups’ wound areas on the 4th, 7th, 14th, and 21st days
after DTI induction were as follows: 4th day, 50.60 ±
3.316 mm2 vs. 44.46 ± 2.197 mm2 (P < 0.05); 7th day,
47.50 ± 1.467 mm2 vs. 37.77 ± 1.110 mm2 (P < 0.05); 14th
day, 33.73 ± 1.326 mm2 vs. 16.64 ± 1.197 mm2 (P < 0.05);
and 21st day, 22.89 ± 0.835 mm2 vs. 10.32 ± 0.447 mm2
(P < 0.05), respectively (Additional file 1: Fig. S2B).
bFGF improved muscle regeneration and inhibited
fibrosis
HE staining was carried out to examine tissue histology
at various time points after DTI induction. Broadened
interstitial space, structural fractures, and even mild
edema were observed in injured muscle tissue compared
to normal uninjured tissue, suggesting the degeneration
of skeletal muscle in regions of compressed muscle in
PUs (Fig. 1a). In addition, while high infiltration of in-
flammatory cells likely intermingled with proliferating
myoblasts and other cell types (e.g., pericytes and fibro-
adipogenic precursors) was observed in injured rat
administrated saline, the degree of inflammatory cell
(mixed population of neutrophils and macrophages)
infiltration was reduced on the 4th day after injured in
rats treated with bFGF. Few newly regenerated myotubes
and myofibers (centro-nucleated), which are the index of
muscle regeneration, were found in saline group, while
application of bFGF obviously increased the centro-
nucleated myofibers on the 7th and 14th days after in-
jury. In addition, in the bFGF group, most damaged
myofibers were cleared and replaced by newly formed
myofibers containing centralized nuclei as compared to
saline group. This was evidenced by a smaller number
of interstitial nuclei on the 14th day after DTI. Fur-
thermore, interstitial space was smaller, and skeletal
muscle cells were more uniform on the 21st day after
injury in the bFGF-treated rats compared to the
saline-treated rats.
To characterize the fibrotic area in injured muscle tis-
sues, Masson’s trichrome staining was performed. In the
bFGF group, collagen deposition, a measure of fibrosis,
was notably lower than that in the saline group on the
7th, 14th, and 21st days after injury, while no difference
in collagen deposition was observed on the 4th day, but
more myofibers were found in bFGF-treated group
(Fig. 1b). These results indicate that the administration
of bFGF enhanced injured skeletal muscle regeneration,
prevented collagen deposition, and improved muscle
recovery after injury.
Enhancement of proliferation and angiogenesis by bFGF
administration
Our immunohistochemistry results showed that the cell
proliferation marker proliferating cell nuclear antigen
(PCNA)-positive cells were found both in normal group
and PU group, the number of PCNA-positive cells was
much higher after DTI, suggesting compensatory repair
was activated after injury. The number of PCNA-posi-
tive cells was increased 2.3-fold on the 4th day after
injury (P < 0.01), peaked on the 7th day (2.5-fold, P <
0.01), and was induced 1.3-fold (P < 0.05), and 2.1-fold
(P < 0.05) on the 14th and 21st days after bFGF treat-
ment, respectively. These results suggest that bFGF
contributes to myocyte proliferation and regeneration in
damaged skeletal muscle tissue (Fig. 2a, c). Similar
temporal change expression was observed for CD31, an
endothelial cell marker. The number of CD31-positive
cells was up-regulated 1.4-fold (P < 0.05) on the 4th day,
peaked on the 7th day (1.8-fold, P < 0.05), and was in-
duced 1.7-fold (P < 0.05) and 1.2-fold (P > 0.05) on the
14th and 21st days after the administration of bFGF, re-
spectively (Fig. 2b, d). Capillary density was detected by
CD31 immunofluorescence staining. Consistent with pre-
vious data, labeling of vasculature by CD31 immunofluor-
escence showed that bFGF treatment induced greater
neovascularization around injury area compared to saline
administration. Treatment with bFGF induced a 1.4-fold
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(P < 0.05), 1.6-fold (P < 0.05), 1.5-fold (P < 0.05), and 1.2-
fold (P > 0.05) increase in the number of vascular at 4th,
7th, 14th, and 21st days after injury, respectively, suggest-
ing that bFGF effectively promoted angiogenesis and im-
proved the conditions of ischemia reperfusion injury in
PUs (Fig. 2e, f ). Taken together, the results demon-
strated that the level of neovascularization was much
higher in bFGF group on the 7th and 14th days after
injury, likely due to the known role of bFGF in facili-
tating angiogenesis.
bFGF increased expression of myogenic markers
myogenin and MyHC
Protein levels of the myogenic markers myogenin and
MyHC were detected by western blot. Levels of myo-
genin were markedly up-regulated in the bFGF group
compared to those in the saline group. Specifically, bFGF
treatment resulted in myogenin levels that were induced
2.4-fold (P < 0.05) on the 4th day, peaked on the 7th day
(3.2-fold, P < 0.05), were induced 1.3-fold (P < 0.05) on
the 14th day, and were significantly decreased (0.2-fold,
P < 0.05) on the 21st day (Fig. 3a, b). The protein levels
of MyHC were also notably increased in bFGF group
compared to the saline group. The protein levels of
MyHC were induced 1.4-fold on the 4th day (P > 0.05),
peaked on the 7th day (2.2-fold, P < 0.05) and 14th day
(2.1-fold, P < 0.05), and were induced 1.6-fold (P < 0.05)
on the 21st day (Fig. 3a, c). Immunofluorescence stain-
ing showed that myogenin was distributed in the nuclei
of the skeletal muscle cells. Consistent with results of
western blot, immunofluorescence staining showed that
bFGF administration, compared to saline administration,
increased the number of myogenin-positive cell 1.7-fold
(P > 0.05), 3.6-fold (P < 0.05), 1.3-fold (P < 0.05), and 0.5-
fold (P < 0.05) on the 4th, 7th, 14th, and 21st days after
injury, respectively (Fig. 3d, e).
bFGF up-regulated the phosphorylation of Akt and mTOR
Activation of the PI3K/Akt/mTOR signaling pathway
protects the heart against ischemia/reperfusion injury
[19]. To investigate whether PI3K-Akt is involved in
muscular regeneration, levels of phosphorylated Akt,
and mTOR, which are the active forms of the proteins,
were determined by western blot analysis. Levels of p-
Akt were significantly decreased (0.7-fold, P < 0.05) after
treatment with bFGF compared to saline group on the
4th day after injury. In contrast, on the 7th, 14th, and
21st days after injury, p-Akt levels were induced 1.7-fold
(P < 0.05), 2.3-fold (P < 0.05), and 1.8-fold (P < 0.05) in
the bFGF group compared to the saline group (Fig. 4a,
b). A similar temporal expression pattern was found for
p-mTOR. Specifically, p-mTOR levels were induced 0.4-
fold (P < 0.05), 1.6-fold (P < 0.05), 1.4-fold (P < 0.05), and
2.0-fold (P < 0.05) in bFGF group on the 4th, 7th, 14th,
and 21st days after injury, respectively (Fig. 4a, c). The
up-regulation of the activities of these proteins suggest
that the PI3K/Akt/mTOR signaling pathway is involved
in the protection of bFGF in skeletal muscle regener-
ation after DTI.
Fig. 1 bFGF improved muscle regeneration and inhibited fibrosis. a HE staining. The elevation of area of interstitial space (star), structural
fractured (arrow), and mild edema were found in injured muscle tissues on the 0th day. Numerous of inflammatory cells infiltrating (triangle) were
found in saline group, while bFGF inhibited inflammatory cells infiltrating (triangle) on the 4th day. bFGF increased centro-nucleated myofibers
(arrow) on the 7th and 14th days. b Observation of fibrosis distributed in injured muscle tissue by Masson’s trichrome staining. Injured muscle
tissues containing collagen deposition (blue) and myofibers (red) were analyzed. Injured muscle tissues treated with bFGF showed a significant
reduction in collagen deposition and increased myofibers within the areas of injury compared with saline group on the 7th, 14th, and 21st days
Shi et al. Burns & Trauma  (2016) 4:26 Page 4 of 10
Fig. 2 (See legend on next page.)
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Fig. 2 Enhancement of proliferation and angiogenesis by bFGF administration. a Photographs showing PCNA immunohistochemistry in saline
group and bFGF group (×200). b Photographs showing CD31 immunohistochemistry (arrow) in two groups (×200). c, d Graph of PCNA and
CD31 immunohistochemistry in two groups. e Photographs showing CD31 immunofluorescence (arrow) on the 7th and 14th days in two groups
(×200). f Graph of CD31 immunofluorescence in two groups. Data are expressed as mean ± SEM (n = 6). *P < 0.05 compared with saline group
Fig. 3 bFGF increased expression of myogenic markers myogenin and MyHC. a Western blot analysis of myogenin and MyHC protein expression in
skeletal muscle tissues of saline group and bFGF group at indicated time. Actin was used as the loading control and for band density normalization. All of
the experiments were repeated three times. b, c The optical density analysis of myogenin and MyHC protein. Data are expressed as Mean ± SEM (n= 3).
d Photographs showing myogenin immunofluorescence (green, red arrow in merge pictures) on the 7th and 14th days in two groups (×200). e Graph of
myogenin immunofluorescence in two groups. Data are expressed as mean ± SEM (n= 6). *P< 0.05 compared with saline group
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Discussion
PU is a serious and challenging health problem due to its
widely variable and complex pathophysiology. The devel-
opment of DTI after injury is multifactorial and mechanis-
tically complex. The results in this study show that bFGF
protected against compression-induced pathohistological
damage in skeletal muscle through the promotion of cell
proliferation, neovascularization, and up-regulation of
MyHC and myogenin protein levels. We also suggest that
activation of PI3K/Akt/mTOR signaling pathway may be
involved in the regenerative effects of bFGF on injured
skeletal muscle.
The major repair processes in response to muscle in-
jury consist of a destruction phase, a repair phase, and a
remodeling phase [9]. The destruction phase is charac-
terized by the formation of a hematoma, necrosis of
myofibers, degeneration, and inflammatory cell infiltra-
tion [20]. In our study, compressed muscle injury (in the
saline group) leads to histopathological characteristics
consistent with those of the destruction phase, specific-
ally loss of muscle fibers, decreased fiber size, cellular
swelling, inflammation infiltration, multiple focal necro-
sis, massive nuclei aggregation in interstitial space, and
excess collagen deposition. These results are consistent
with findings reported by Siu et al. [21]. Since the pres-
ence of degenerative characteristics was demonstrated in
the underlying muscle tissue, this experimental model
resembled pressure-induced DTI in a clinical situation
[1, 22]. Excessive development of fibrosis hinders muscle
regeneration and prevents full recovery, and reduction
of fibrosis improves muscle regeneration in injured skel-
etal muscle [23]. In the current study, administration of
bFGF accelerated wound healing and decreased wound
areas. These changes were associated with increased for-
mation of new myofibers and decreased fibrosis, ultim-
ately improving recovery of skeletal muscle tissue.
Cell proliferation plays an essential role in the repair
and regeneration of a number of types of damaged tis-
sues. Expression of PCNA is also induced after skeletal
injury. Song et al. demonstrated that PCNA significantly
increased after burn and was associated with increased
gene and protein expression of the myogenesis markers
Pax7 and myogenin [24]. Moreover, muscle injury in-
duced by intramuscular injection of bupivacaine hydro-
chloride in the soleus also significantly up-regulated
[25], suggesting that up-regulation of cell proliferation
also facilitates injured muscle regeneration. In our study,
though PCNA-positive cells were found both in normal
group and PU group, the number of PCNA-positive cells
was higher in those with PUs. In addition, the number
of PCNA-positive cells was significantly increased after
bFGF treatment.
Impairment of the microcirculation after ischemic/re-
perfusion injury is a critical component in the
Fig. 4 bFGF up-regulated the phosphorylation of Akt and mTOR. a Western blot analysis of phosphorylation of Akt and mTOR levels in skeletal
muscle tissues of saline group and bFGF group at indicated time. Actin was used as the loading control, and total Akt and mTOR were used for
band density normalization. All of the experiments were repeated three times. b, c The optical density analysis of phosphorylation of Akt and
mTOR levels. Data are expressed as mean ± SEM (n = 3). *P < 0.05 compared with saline group
Shi et al. Burns & Trauma  (2016) 4:26 Page 7 of 10
pathogenesis of DTI. Vascular ingrowth into the muscle
injury site is necessary to provide an adequate supply of
oxygen and nutrients to the injured tissue and is corre-
lated with the speed and quality of tissue repair. The ef-
fects of bFGF on neovascularization, along with other
positive effects on tissue repair, have been investigated
by the administration of bFGF on ischemia/reperfusion
animal models [26]. Lee et al. demonstrated that local
bFGF infusion into an ischemic limb not only promoted
increased blood vessel density in the distal ischemic
muscles but was also associated with the restoration of
impaired muscle function [27]. Thus, it is reasonable to
speculate that bFGF promotes angiogenesis, thereby in-
creasing the blood supply to the injury site and facilitat-
ing injured muscle regeneration. Consistent with this
idea, our data demonstrated that the number of CD31-
positive cells and the capillary density at the injury site
were significantly up-regulated after bFGF treatment.
Myogenin belongs to the family of myogenic regula-
tory factors (MRFs) which are composed of MyoD,
myogenin, myf-5, and myf-6, and its expression is rap-
idly followed by terminal withdrawal from the cell cycle
and expression of muscle-specific structural proteins
[28]. MRFs play an important role in myoblast differen-
tiation and in the formation of multinucleated myo-
tubes, facilitating injured muscle regeneration [29, 30].
Mofarrahi et al. showed that Angiopoietin-1 increased
expression of the MRFs (MyoD and Myogenin) and en-
hanced skeletal muscle regeneration in response to
fiber injury [31]. The MyHC protein is critical for
physiological muscle function [32], and like MRFs,
serves as a myogenic marker in muscle development
and regeneration. In our study, myogenin expression
level peaked on the 7th, and 14th day after injury, and
significantly decreased on the 21st day, suggesting that
bFGF facilitated myogenesis, as indicated by higher
MyHC expression levels. This temporal profile of myo-
genin expression implied that bFGF exerted its bio-
logical roles during the first 2 weeks after injury.
Muscle mass is controlled by complex cell signaling
pathways that regulate muscle protein synthesis and
degradation. The serine/threonine protein kinase Akt is
an important mediator of phosphatidylinositol-3 kinase
(PI3K) signaling in different tissues and regulates mul-
tiple aspects of cellular functions, including survival,
growth, and metabolism [33]. The mammalian target of
rapamycin (mTOR), a downstream component of the
PI3K-Akt signaling pathway, plays a regulatory role in
translation initiation, protein synthesis, and muscle
hypertrophy [34]. Akt has been shown to induce tran-
scription of muscle-specific genes, resulting in myoblast
differentiation [35, 36]. Furthermore, the Akt/mTOR
pathway is a crucial regulator of skeletal muscle hyper-
trophy and can prevent muscle atrophy [34]. Previous
studies have reported that PI3K activity is necessary for
the activation of the myogenic program [37]. Consistent
with this, the PI3K-Akt-mTOR pathway is activated in
muscles after acute contusion in mice [38]. bFGF-
mediated activation of the PI3K-Akt pathway is a
potent mediator of muscle differentiation [39] and
protects the heart against ischemia/reperfusion injury
[19, 40]. In our study, bFGF treatment significantly in-
duced phosphorylation of Akt and mTOR, thereby acti-
vating them. The phosphorylation of Akt and mTOR
was in turn associated with increased cell proliferation,
differentiation, and myogenesis. However, on the 4th
day after injury, phosphorylation of Akt and mTOR
was notably decreased in bFGF-treated rats compared
to those in the saline group. We speculated that this
decrease in the bFGF-treated group may be related to
macrophage phagocytosis, which leads to bFGF degrad-
ation. Therefore, the development of new drug delivery
systems that can protect the protein against degrad-
ation should be the focus of future studies.
As we described above, satellite cells function as
adult muscle stem cells and are responsible for regen-
erating muscle. Previous studies have demonstrated
that bFGF mRNA is expressed by skeletal satellite
cells [41] and that bFGF enhances satellite cell prolif-
eration [42]. Another study reported that fibroblast
growth factor receptors (FGFR1 and FGFR4) were
expressed at relatively high levels in quiescent satellite
cells, and ablation of FGFR1 impaired bFGF-mediated
proliferation of satellite cells at the myofibers niche
but did not abolish the capacity for muscle regener-
ation [43], suggesting a more complex relationship
between FGF-mediated satellite cell proliferation and
regeneration. However, in our study, we did not ex-
plore the intricacies of the mechanisms underlying
bFGF-mediated satellite cell proliferation and regener-
ation in the DTI model, so further study is warranted.
The results of our study showed that bFGF activated
PI3K-Akt-mTOR signaling pathway, but it remains
unclear that whether this pathway is an essential
pathway improving recovery of injured skeletal
muscle, though Akt/mTOR pathway is a crucial regu-
lator of skeletal muscle hypertrophy and prevents
muscle atrophy [34]. Further studies using knock-out
mice should explore the role of the PI3K-Akt-mTOR
signaling in the recovery of injured skeletal muscle.
Another defect in our study is whether ERK1/2 is in-
volved in bFGF-induced injured skeletal muscle recov-
ery. As we have known, ERK1/2 signaling is one of
downstream pathways of FGF family protein [44], and
activation of ERK1/2 is also related to injured muscle
regeneration [45]. Therefore, whether ERK1/2 signal-
ing pathway is involved in the bFGF-promoted in-
jured muscle recovery needs further study.
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Conclusions
Our results showed that DTI induced skeletal muscle
degradation and that bFGF improved injured skeletal
muscle recovery. We propose that bFGF improves
skeletal muscle recovery by promoting cell prolifera-
tion and angiogenesis and facilitating myogenesis via
activating the PI3K-Akt-mTOR signaling pathway.
Our findings suggest that bFGF can be developed as
a potential therapeutic candidate for the treatment of
PUs, especially DTI, in clinical trials.
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